Hepatoma Arterial-Embolisation Prognostic (HAP) Score of Kadalayil et al Predicting the Prognosis of a Patient with a Hepatocellular Carcinoma Treated with Transarterial Embolisation (TAE)

Description

Kadalayil et al developed a prognostic score for patients with a hepatocellular carcinoma who underwent transarterial embolisation (TAE). This can help to predict the outcome for the patient. The authors are from multiple cancer centers in England.

Patient selection: hepatocellular carcinoma, candidate for TAE

Parameters:

(1) serum albumin in g/L

(2) serum total bilirubin in µmol/L

(3) serum AFP in ng/mL

(4) diamteter of the dominant tumor in cm

Parameter	Finding	Points
serum albumin	< 36 g/L	1
	>= 36 g/L	0
serum total bilirubin	<= 17 µmol/L	0
	> 17 µmol/L	1
serum AFP	<= 400 ng/mL	0
	> 400 ng/mL	1
diameter	<= 7 cm	0
	> 7 cm	1

hepatoma arterial-embolisation prognostic (HAP score =

= SUM(points for all 4 parameters)

Interpretation:

• minimum score: 0

• maximum score: 4

Score	Prognostic Group	Median Survival
0	A	27.6 months
1	B	18.5 months
2	C	9 months
3 or 4	D	3.6 months

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10